Onglyza and Pancreatic Cancer
According to the American Diabetes Association, nearly 28 million Americans suffer from type 2 diabetes. This number is expected to grow as the population ages. The pharmaceutical industry sees this as a fertile marketplace for new type 2 diabetes medications. Among this new generation of drugs is Onglyza (saxagliptin), which was approved by the U.S. Food and Drug Administration (FDA) in 2009.
The medication grew rapidly in popularity, garnering more than $700 million in sales by 2011. Part of the reason for its popularity is that Onglyza doesn’t cause the weight gain that has been associated with other type 2 diabetes medications. But Onglyza’s popularity may begin to wane since studies in recent years have linked the medication to serious side effects, such as heart failure and pancreatitis.
Another danger of the drug is that chronic pancreatitis has been known to lead to pancreatic cancer. In fact, many patients who were treated with Onglyza have developed pancreatic cancer, prompting lawsuits against the drug’s manufacturers, pharmaceutical giants AstraZeneca and Bristol-Myers Squibb.If you were prescribed Onglyza and suffered side effects like diarrhea, nausea, vomiting, urinary tract infection, or pancreatitis, you may be able to pursue compensation for your injuries. But filing an injury claim against huge corporations like AstraZeneca and Bristol-Myers Squibb is no easy task. Such companies and their insurers employ armies of lawyers to fight off injury lawsuits.
To secure a settlement worthy of your injuries, you will need the representation of an aggressive and tenacious pharmaceutical litigation attorney. Onglyza pancreatic attorneys at the law offices of Farah & Farah have been handling personal injury claims against large corporations for over 35 years. We are now investigating Onglyza-related injuries nationwide. Let us put our knowledge and experience behind your case and get you the settlement you deserve. Call Farah & Farah today for a free consultation. Call (800) 533-3555.